Gerardo Carrión serves as the Chief Financial Officer at Frontier Medicines, where he plays a pivotal role in steering the financial strategy of a clinical-stage biopharma company that is at the forefront of precision medicine, particularly in oncology and immunology. With a robust background as...
Gerardo Carrión serves as the Chief Financial Officer at Frontier Medicines, where he plays a pivotal role in steering the financial strategy of a clinical-stage biopharma company that is at the forefront of precision medicine, particularly in oncology and immunology. With a robust background as a biopharma investment banker spanning over 12 years, Gerardo has honed his expertise in global and cross-border strategic advisory, focusing on computationally-enabled drug discovery. His experience includes advising C-suite executives and boards of directors from both established global biopharma firms and emerging small-cap biotech companies, enabling them to navigate complex financial landscapes and make informed strategic decisions.
At Frontier Medicines, Gerardo leverages his deep understanding of financial modeling, valuation, and corporate finance to support the company's proprietary chemoproteomics discovery engine, which integrates covalent chemistry with advanced machine learning techniques. His unique blend of skills, including proficiency in Python programming and financial analysis, allows him to contribute to the innovative approaches Frontier Medicines employs in drug discovery. As a dual citizen of the US and Spain, Gerardo brings a global perspective to his role, enhancing the company's ability to engage with diverse markets and stakeholders.
In addition to his financial acumen, Gerardo's passion for AI and machine learning in drug discovery reflects his commitment to advancing the biopharma industry. His journey from a former violinist to a key player in the financial realm of biotechnology underscores his multifaceted talents and dedication to improving patient outcomes through innovative therapies. As Frontier Medicines continues to push the boundaries of precision medicine, Gerardo's leadership and insights will be instrumental in driving the company's growth and success in the competitive biopharma landscape.
